en
Scientific article
English

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

Published inLancet. Infectious diseases, vol. 15, no. 10, p. 1156-1166
Publication date2015
Abstract

Safe and effective vaccines against Ebola could prevent or control outbreaks. The safe use of replication-competent vaccines requires a careful dose-selection process. We report the first safety and immunogenicity results in volunteers receiving 3 × 10(5) plaque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expressing the Zaire Ebola virus glycoprotein (rVSV-ZEBOV; low-dose vaccinees) compared with 59 volunteers who had received 1 ×10(7) pfu (n=35) or 5 × 10(7) pfu (n=16) of rVSV-ZEBOV (high-dose vaccinees) or placebo (n=8) before a safety-driven study hold.

Citation (ISO format)
CSAKI HUTTNER, Angela et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. In: Lancet. Infectious diseases, 2015, vol. 15, n° 10, p. 1156–1166. doi: 10.1016/S1473-3099(15)00154-1
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1473-3099
571views
0downloads

Technical informations

Creation09/16/2015 2:40:00 PM
First validation09/16/2015 2:40:00 PM
Update time03/14/2023 11:44:18 PM
Status update03/14/2023 11:44:17 PM
Last indexation08/29/2023 7:25:56 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack